Bevacizumab Export Market Intelligence: India's 196 Suppliers Shipping to 100 Countries — TransData Nexus 2026

Q: Who are the top bevacizumab exporters from India?

The top bevacizumab exporters from India are: 1. DR.REDDY'S LABORATORIES LTD — $22.1M (47.2% market share); 2. BIOCON BIOLOGICS INDIA LIMITED — $8.6M (18.4% market share); 3. DR REDDY S LABORATORIES LTD — $4.6M (9.9% market share); 4. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $2.1M (4.5% market share); 5. ZYDUS LIFESCIENCES LIMITED — $1.8M (3.8% market share). Together they account for 83.9% of India's total bevacizumab export value.

Q: What is the total export value of bevacizumab from India?

The total export value of bevacizumab from India is $46.9M USD, recorded across 1,408 shipment transactions from 196 active exporters to 100 destination countries. The average shipment value is $33.3K.

Q: Which countries import bevacizumab from India?

India exports bevacizumab to 100 countries worldwide. The top importing countries are: RUSSIA (50.3% share, $23.6M), NETHERLANDS (14.3% share, $6.7M), COLOMBIA (7.9% share, $3.7M), MEXICO (3.6% share, $1.7M), VENEZUELA (3.1% share, $1.4M). These five markets account for 79.3% of total export value.

Q: What is the HS code for bevacizumab exports from India?

The primary HS code for bevacizumab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of bevacizumab exports from India?

The average unit price for bevacizumab exports from India is $147.11 USD per unit, with prices ranging from $0.00 to $3098.55 depending on formulation, packaging, and order volume. The total market is valued at $46.9M across 1,408 shipments.

Q: Which ports handle bevacizumab exports from India?

The primary ports for bevacizumab exports from India are SAHAR AIR (24.5% of shipments), SAHAR AIR CARGO ACC (INBOM4) (23.2% of shipments), HYDERABAD ACC (INHYD4) (9.4% of shipments), Bombay Air (6.3% of shipments), DELHI AIR CARGO ACC (INDEL4) (3.4% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of bevacizumab?

India is one of the world's leading exporters of bevacizumab due to its large base of 196 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports bevacizumab to 100 countries, demonstrating 51% global market coverage.

Q: What certifications do Indian bevacizumab exporters need?

Indian bevacizumab exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import bevacizumab from India?

There are 346 registered buyers importing bevacizumab from India, spread across 100 countries. The repeat buyer rate is 57.2%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top bevacizumab supplier from India?

DR.REDDY'S LABORATORIES LTD is the leading bevacizumab exporter from India with a market share of 47.2% and total export value of $22.1M across 131 shipments. The top 5 suppliers together control 83.9% of total export value.

Suresh Sormare

Bevacizumab

India Pharmaceutical Trade Intelligence

$46.9M196 Suppliers100 CountriesHS 30021500

ExportsIndia → RUSSIA50.3%India → NETHERLANDS14.3%

ImportsSWITZERLAND → India$1.2B GERMANY → India$344.1M

#1 Buyer: JSC R-PHARM

Bevacizumab Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Bevacizumab to the World

Between 2022 and 2026, India exported $46.9M worth of bevacizumab across 1,408 verified shipments to 100 countries — covering 51% of world markets in the Advanced Oncology segment. The largest destination is RUSSIA (50.3%). DR.REDDY'S LABORATORIES LTD leads with a 47.2% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Bevacizumab export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Bevacizumab export data snapshot — $46.9M · 196 exporters · 100 countriesTransData Nexus · Indian Customs Data

Top Bevacizumab Exporters from India

196 active exporters · Ranked by export value

View all 196 →

Top Bevacizumab Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	DR.REDDY'S LABORATORIES LTD	$22.1M	131	15	47.2%
2	BIOCON BIOLOGICS INDIA LIMITED

Top Countries Importing Bevacizumab from India

100 destination markets · Ranked by import value

All 100 countries →

Top Countries Importing Bevacizumab from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	RUSSIA	$23.6M	50.3%
2	NETHERLANDS	$6.7M	14.3%
3	COLOMBIA	$3.7M	7.9%
4	MEXICO	$1.7M	3.6%
5	VENEZUELA	$1.4M	3.1%
6	DOMINICAN REPUBLIC	$1.0M	2.2%
7	KENYA	$930.4K	2.0%
8	EGYPT	$718.4K	1.5%
9	MALDIVES	$629.7K	1.3%
10	BRAZIL	$505.0K	1.1%

RUSSIA is India's largest bevacizumab export destination, absorbing 50.3% of total exports worth $23.6M. The top 5 importing countries — RUSSIA, NETHERLANDS, COLOMBIA, MEXICO, VENEZUELA — together account for 79.3% of India's total bevacizumab export value. The remaining 95 destination countries collectively receive the other 20.7%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Bevacizumab to India?

8 origin countries · Total import value: $1.5B

India imports bevacizumab from 8 countries with a combined import value of $1.5B. The largest supplier is SWITZERLAND ($1.2B, 4 shipments), followed by GERMANY and BELGIUM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Bevacizumab to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	SWITZERLAND	$1.2B	4	77.3%
2	GERMANY	$344.1M	54	22.7%
3	BELGIUM	$125.2K	7	0.0%
4	UNITED STATES	$33.1K	20	0.0%
5	UNITED KINGDOM	$5.5K	8	0.0%
6	CHINA	$768	4	0.0%
7	SOUTH AFRICA	$44	4	0.0%
8	SDNF	$11	1	0.0%

SWITZERLAND is the largest supplier of bevacizumab to India, accounting for 77.3% of total import value. The top 5 origin countries — SWITZERLAND, GERMANY, BELGIUM, UNITED STATES, UNITED KINGDOM — together supply 100.0% of India's bevacizumab imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Bevacizumab

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, bevacizumab is approved under the brand name Avastin, with the original approval granted to Genentech, Inc. The FDA has also approved biosimilar versions, such as Mvasi (approved in September 2017) and Zirabev (approved in June 2019). These approvals are documented in the FDA's Orange Book. The regulatory pathway for biosimilars involves demonstrating high similarity to the reference product without significant clinical differences. Given the substantial number of Indian exporters (196) involved in bevacizumab exports, compliance with FDA regulations, including adherence to Good Manufacturing Practices (GMP) and successful completion of the Biologics License Application (BLA) process, is imperative for market entry into the U.S.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval of medicinal products. Bevacizumab is marketed under various names, including Avastin. Biosimilar approvals have been granted, such as Onbevzi, which received marketing authorization on January 11, 2021. However, Onbevzi's authorization was withdrawn on December 11, 2023, at the request of the marketing authorization holder for commercial reasons. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns closely with EMA standards, requiring comprehensive data on quality, safety, and efficacy for marketing authorization. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety.

3WHO Essential Medicines & Global Standards

Bevacizumab is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in treating various cancers. The WHO Prequalification Programme evaluates medicines to ensure they meet global standards of quality, safety, and efficacy, facilitating procurement by international agencies. Bevacizumab formulations are expected to comply with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistency and quality across different markets.

4India Regulatory Classification

In India, bevacizumab is classified under Schedule H of the Drugs and Cosmetics Rules, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest data, bevacizumab is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical products leaving the country.

5Patent & Exclusivity Status

The primary patents for bevacizumab have expired, leading to increased generic competition and the development of biosimilars. This has resulted in more affordable options for patients and expanded market opportunities for manufacturers. However, companies must navigate complex patent landscapes and ensure their products do not infringe on existing intellectual property rights.

6Recent Industry Developments

In May 2025, the FDA approved a new biosimilar version of bevacizumab, further increasing competition in the U.S. market. In July 2025, the EMA updated its guidelines on biosimilar development, emphasizing the need for robust analytical and clinical data to demonstrate similarity to reference products. In September 2025, the NPPA conducted a review of anti-cancer drug prices, including bevacizumab, to assess affordability and accessibility for patients in India. In November 2025, the WHO added a new formulation of bevacizumab to its Model List of Essential Medicines, recognizing its importance in treating additional cancer types. In January 2026, the DGFT implemented stricter export controls on biological products, including bevacizumab, to ensure quality standards are maintained in international markets.

These developments reflect the dynamic nature of the pharmaceutical industry and the importance of regulatory compliance in maintaining market access and ensuring patient safety.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Bevacizumab

Retail & reference prices across 9 markets vs. India FOB export price of $147.11/unit

Global Price Benchmark for Bevacizumab across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$1,500	USD	Pricing data sourced from the FDA's Orange Book and Medicare reimbursement rates as of March 2026.
United Kingdom	Approximately $1,560	GBP	According to the NHS Drug Tariff, as of March 2026.
Germany	Approximately $1,540	EUR	Based on data from the Federal Institute for Drugs and Medical Devices (BfArM), March 2026.
Australia	Approximately $1,400	AUD

Supply Chain Risk Assessment — Bevacizumab

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Bevacizumab, a monoclonal antibody used in various cancer treatments, requires complex manufacturing processes involving specific active pharmaceutical ingredients (APIs) and key starting materials (KSMs). India, a major producer of generic pharmaceuticals, often relies on China for a significant portion of these KSMs. China controls approximately 70–80% of the global KSM supply and 60–70% of intermediate supplies, making it a dominant player in the pharmaceutical raw material market.

This dependency poses a risk to the supply chain, as any disruptions in China's production or export activities can directly impact India's ability to manufacture Bevacizumab. For instance, geopolitical tensions, environmental regulations, or logistical challenges in China can lead to delays or shortages in KSM availability, thereby affecting the production timelines and costs for Indian pharmaceutical companies.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 indicates a high concentration among Bevacizumab exporters in India. The top five exporters account for 83.9% of the total export value, with DR. REDDY'S LABORATORIES LTD alone contributing 47.2% ($22.1 million USD). This significant concentration increases the risk of supply chain disruptions, as any operational issues within these key companies could substantially impact global availability.

Access Complete Bevacizumab Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,408 transactions across 100 markets.

Request Demo View Pricing

Frequently Asked Questions — Bevacizumab Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top bevacizumab exporters from India?

The leading bevacizumab exporters from India are DR.REDDY'S LABORATORIES LTD, BIOCON BIOLOGICS INDIA LIMITED, DR REDDY S LABORATORIES LTD, and 9 others. DR.REDDY'S LABORATORIES LTD leads with 47.2% market share ($22.1M). The top 5 suppliers together control 83.9% of total export value.

What is the total export value of bevacizumab from India?

The total export value of bevacizumab from India is $46.9M, recorded across 1,408 shipments from 196 active exporters to 100 countries. The average shipment value is $33.3K.

Which countries import bevacizumab from India?

India exports bevacizumab to 100 countries. The top importing countries are RUSSIA (50.3%), NETHERLANDS (14.3%), COLOMBIA (7.9%), MEXICO (3.6%), VENEZUELA (3.1%), which together account for 79.3% of total export value.

What is the HS code for bevacizumab exports from India?

The primary HS code for bevacizumab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Bevacizumab

Bevacizumab

Top Bevacizumab Exporters from India

Top Countries Importing Bevacizumab from India

Who Supplies Bevacizumab to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Bevacizumab

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Bevacizumab

Supply Chain Risk Assessment — Bevacizumab

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Bevacizumab Trade Intelligence

Frequently Asked Questions — Bevacizumab Exports from India

Who are the top bevacizumab exporters from India?

What is the total export value of bevacizumab from India?

Which countries import bevacizumab from India?

What is the HS code for bevacizumab exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of bevacizumab exports from India?

Which ports handle bevacizumab exports from India?

Why is India a leading exporter of bevacizumab?

What certifications do Indian bevacizumab exporters need?

How many buyers import bevacizumab from India?

What is the market share of the top bevacizumab exporter from India?

Analysis Methodology